Catalyst

Slingshot members are tracking this event:

Gilead Begins Phase 3 Study of Eleclazine for Treatment of Long QT-3 Syndrome - Data Readout Expected H1 of 2017 - Terminated

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD

100%

Additional Information

Additional Relevant Details The Phase 3 study of Eleclazine for the treatment in patients with Long QT-3 syndrome is projected to complete February 2017, with a data readout expected in the first half of 2017.
http://investors.gil...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Eleclazine, Gs-6615, Long Qt-3 Syndrom, Data Readout